PSNL - Personalis, Inc. Company Cash Volume

PSNL (Personalis) - company brandmark

Amidst fierce competition for market share in clinical testing, Personalis, Inc. (PSNL) is implementing automated tumor analysis systems to eliminate manual labor. A stable staff of bioinformaticians supports this technological growth. The organization's cash balances demonstrate liquidity dynamics, while the 0.19 metric serves as the target level, helping to assess management's financial strategy during periods of market optimism.

Company Cash Funds: Personalis Inc (PSNL) for 07/04/2022 - 11/21/2026

Analytical breakdowns and data insights for company Personalis Corp (PSNL)

- stock value and consensus price forecast:
Fundamental valuation:personalis.com
Signature product of Personalis Inc

This metric measures the liquid capital reserve on the balance sheet, allowing investors to filter out market noise and assess the issuer's actual financial stability. By analyzing the cash structure, an investor can see the current value of 0.19, which is critically important for Personalis, Inc. (PSNL) amid its expansion in the precision oncology diagnostics market and the need to fund growing demand from medical centers.

Main competitors

Company Cash Volume ONC|HALO - Company Cash Reserve|Revolution Medicines - Company Cash on Hand|Company Cash Volume Ascentage Pharma AAPG|CGON - Company Cash Funds|Company Total Cash Volume URGN|BCAX: Company Cash Volume|Company Cash and Cash Equivalents ERAS|Company Cash on Hand DCTH|Company Cash Reserve Y-mAbs Therapeutics Inc YMAB|Company Cash Volume AURA|CADL (Candel Therapeutics, Inc.) - Company Cash Balance|Company Cash Funds Accuray Inc ARAY|Company Liquid Assets SELLAS Life Sciences Group Inc. (SLS)|actuatetherapeutics.com - Company Cash Volume|Company Cash Reserve Citius Oncology|HURA: Company Cash Volume|Company Total Cash Volume TARA (Protara)|FATE (fatetherapeutics.com) - Company Cash Volume|Company Cash Reserve Aadi Bioscience WHWK|Company Cash Volume TCRX|CSBR - Company Cash Reserve|XBiotech - Company Cash on Hand|CEL-SCI Corporation (CVM) - Company Cash Reserve|OSTX - Company Cash Funds|Company Cash Reserve Radiopharm Theranostics Ltd|ARTV (artivabio.com) - Company Cash on Hand|ANL (Adlai Nortye Ltd) - Company Cash Funds|Company Cash on Hand VERU|Tempest Therapeutics (TPST) - Company Liquid Assets|Company Cash Volume XLO|Company Cash on Hand Renovaro RENB|Company Cash Volume MURA (Mural Oncology PLC)|KAPA - Company Cash on Hand|OnKure Therapeutics - Company Cash Volume|w2.cytomed.sg - Company Total Cash Amount|Curis Corp (CRIS) - Company Cash Funds|Company Cash Reserve Apollomics Corp (APLM)|Company Cash Funds Tharimmune|Company Cash Volume advanbiomed.com|Company Cash Funds Genprex, Inc (GNPX)|Company Liquid Assets Calidi Biotherapeutics, Inc.|Company Cash Volume SBFM (Sunshine Biopharma Inc.)|XBIO - Company Cash on Hand|SLRX: Company Cash on Hand|Company Cash Balance PPBT (Purple Biotech Ltd.)|AONC: Company Cash Volume|Company Cash Reserve BeOne Medicines (BGNE)|Company Cash Funds Checkpoint Therapeutics, Inc.|Company Cash on Hand Elevation Oncology (ELEV)|Company Cash Funds iCAD Corp (ICAD)|Company Cash on Hand Ikena IKNA|Company Cash Volume NTBL (notablelabs.com)|VIRX - Company Cash on Hand|MOR: Company Cash on Hand|NAYA - Company Cash Volume|Ascentage Pharma (AAPGV) - Company Cash Funds